Chest
Volume 142, Issue 4, Supplement, October 2012, Page 1027A
Signs and Symptoms of Chest Diseases | October 2012Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1)
Section snippets
Abstract
SESSION TYPE: Late-Breaking Abstracts
PRESENTED ON: Tuesday, October 23, 2012 at 04:30 PM - 05:45 PM
PURPOSE: Riociguat is the first member of a novel class of compounds, the soluble guanylate cyclase (sGC) stimulators. With a dual mode of action, it synergizes with endogenous nitric oxide (NO) and also directly stimulates sGC independent of NO availability. Therefore, riociguat may restore the NO-sGC-cGMP pathway. The Phase III, double-blind, randomized, placebo-controlled PATENT-1 study
References (0)
Cited by (0)
Copyright © 2012 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.